Clinical Trial Highlights

The Clinical Trial Highlights section of JPD was launched at the start of 2019 and is devoted to raising awareness of the clinical trial landscape in Parkinson’s, promoting discussion and progress in the conduct and outcome of studies. All content in this section is freely available to read, download and share.

You can find in this section of the website (below) an overview of articles published in regular issues of JPD. For details of individual trials, go here or click the visual above. For short extracts of the "Phase 3 Trials in Focus" articles, go here. For a list of Clinical Trials Resources, go here.

To search for specific topics, input free text into the search box at the top right of the website. To fine tune the results, put words in quote marks (e.g. "trial" "dyskinesia").

--------------------------------------------------

Clinical Trial Highlights: Articles

Content included in regular (not all) issues of JPD: listed below with the most recent issue at the top; click the link to be taken to the relevant article published in JPD

JPD Volume 11, Issue 3 (2021)
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Research article by Kevin McFarthing, Gary Rafaloff, Marco A.S. Baptista, Richard K. Wyse, and Simon R.W. Stott

JPD Volume 11, Issue 2 (2021)
Clinical Trial Highlights – Kinase Inhibitors
Clinical Trial Highlights: Phase 3 in Focus – Ampreloxetine, Theravance Biopharma

JPD Volume 11, Issue 1 (2021)
Clinical Trial Highlights – Parkinson’s Disease Cognition
Clinical Trial Highlights: Phase 3 in Focus – Tavapadon (see p.26 in the PDF)

JPD Volume 10, Issue 3 (2020)
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Research article by Kevin McFarthing, Susan Buff, Gary Rafaloff, Thea Dominey, Richard K. Wyse, and Simon R.W. Stott; view press release here

JPD Volume 10, Issue 2 (2020)
Clinical Trial Highlights: GLP-1 agonists

JPD Volume 10, Issue 1 (2020)
Clinical Trial Highlights: Infusion Therapies
Clinical Trial Highlights: Phase 3 in Focus – Amneal's IPX203 (see p.15 in the PDF)

JPD Volume 9, Issue 3 (2019)
Clinical Trial Highlights: Dyskinesia
Clinical Trial Highlights: Phase 3 in Focus – Adamas Pharma's Gocovri (see p.451 in the PDF)

JPD Volume 9, Issue 2 (2019)
Clinical Trial Highlights: Gene Therapy for Parkinson's
Clinical Trial Highlights: Phase 3 in Focus – Intec Pharma's Accordian Pill (see p.262 in the PDF)

JPD Volume 9, Issue 1 (2019)
Editorial: Introducing Clinical Trials Highlights
Clinical Trials Highlights: Targeting Alpha-Synuclein
Clinical Trials Highlights: Phase 3 in Focus – Israpidene